NRSN

Neurosense Therapeutics Ltd. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website neurosense-tx.com
Employees(FY) 14
ISIN IL0011809592

Performance

-25.56%

-7.47%

+29.26%

-18.17%

+26.13%

YTD

+92.66%

Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Advanced Technical Analysis

Technical Analysis of NRSN 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 3, Oscillators Score at 36, and a Technical Score of 20, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NRSN

Stock Rank

Recent News & Updates

2024-10-27 20:30
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission(Prnewswire)
2024-10-23 20:30
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients(Prnewswire)
2024-10-14 21:15
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates(Prnewswire)
2024-10-08 21:00
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada(Prnewswire)
2024-10-06 21:00
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting(Prnewswire)
2024-09-23 21:05
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's(Prnewswire)
2024-09-23 21:00
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule(Prnewswire)
2024-08-30 04:30
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification(Prnewswire)
2024-08-07 02:00
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price(Prnewswire)
2024-07-31 21:15
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial(Prnewswire)
2024-07-08 21:27
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression(Prnewswire)
2024-06-30 20:00
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug(Prnewswire)
2024-06-24 02:52
NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-06-23 21:00
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results(Prnewswire)
2024-06-21 04:30
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal(Prnewswire)
2024-05-19 21:00
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit(Prnewswire)
2024-05-13 21:05
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning(Prnewswire)
2024-05-06 20:45
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients(Prnewswire)
2024-05-01 21:19
NeuroSense Announces First Quarter 2024 Business Update(Prnewswire)
2024-04-21 20:30
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease(Prnewswire)
2024-04-17 20:30
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting(Prnewswire)
2024-04-11 20:30
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024(Prnewswire)
2024-04-10 07:16
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement(Prnewswire)
2024-04-08 20:30
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics(Prnewswire)
2024-04-05 08:52
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-04-04 21:29
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update(Prnewswire)
2024-02-20 19:30
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial(Prnewswire)
2024-02-06 20:27
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule(Prnewswire)
2024-01-29 19:30
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024(Accesswire)
2024-01-08 19:45
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts(Prnewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.